Pfizer has not yet accrued the32 COVID infections for its 1st interim analysis: The fact that Pfizer’s first interim has not been triggered suggests the participants enrolled in the trial may have lower exposure to COVID-19 compared to the general population and/or reported COVID infections overestimating the rate of symptomatic infections. We adjusted our assumptions on the infection rate in…
Ease is a greater threat to progress than hardship ~ Denzel Washington If you want to view our weekly...
Humans are addicted to doomsday narratives. I’ve noticed that sometimes people WANT things to be worse than they are,...
A 3-week winning streak for equities came to an end for the S&P 500 (SPX) this past week. April...
Hindsight is 20/20, as they say, but regret is front of mind and stickier than even inflation proposes. When...
The market is testing investors and traders alike. That is what the market tends to do during corrections; it...
Show Me the Money! 2020 was all about beta and understanding how equity markets trade in and around a...
The major indexes posted slight weekly losses last week. The Dow and S&P 500 both fell 0.5% for the...
JPM Market Recap
$0.00
JPM Research Note
$0.00
JP Morgan Market Volatility Report
$0.00
MarketWatch.com – Top Stories
